Achondroplasia Pipeline Expands as 15+ Pharma Companies Advance Targeted Therapies for Dwarfism, Finds DelveInsight | QED Therapeutics, Ascendis Pharma, Tyra Biosciences, BridgeBio

DelveInsight's "Achondroplasia - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing several pipeline drugs in the achondroplasia pipeline landscape. It covers the achondroplasia pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the achondroplasia treatment landscape. Learn more about the evolving achondroplasia pipeline today @ https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Achondroplasia Pipeline Report

• In February 12, 2026, BridgeBio Pharma reported positive Phase 3 topline results for oral infigratinib, demonstrating statistically significant improvements in annualized growth velocity and body proportionality in children with achondroplasia.
• On November 28, 2025, an FDA decision is expected for Ascendis Pharma's navepegritide (TransCon CNP), a once-weekly prodrug currently under Priority Review for the treatment of achondroplasia.
• In mid-2024, Ascendis Pharma revealed interim Phase 2 data for its weekly CNP analog showing growth outcomes comparable to daily vosoritide with a significantly reduced injection burden.
• In late 2023, BridgeBio launched its global Phase 3 program for infigratinib, markng one of the first worldwide trials for an oral delivery option in this patient population.
• In 2023, the FDA expanded the label for BioMarin's VOXZOGO (vosoritide) to include all children with achondroplasia and open epiphyses, including those under five years of age.
• Achondroplasia is the most common form of dwarfism, caused by a gain-of-function mutation in the FGFR3 gene that inhibits linear bone growth.
• DelveInsight's Achondroplasia Pipeline Insight report depicts a growing clinical development space with 15+ active players advancing 13+ pipeline therapies globally.
• Leading achondroplasia companies include QED Therapeutics, Inc. (a BridgeBio company), Ascendis Pharma, Tyra Biosciences, BioMarin, Pfizer, Sanofi, and ProLynx.
• Promising emerging therapies include infigratinib, navepegritide (TransCon CNP), and TYRA-300, which target the FGFR3 and CNP pathways to improve skeletal development.

Download for updates and the latest revolution in achondroplasia care @ https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Achondroplasia Emerging Drugs Profile

• Infigratinib: QED Therapeutics, Inc. / BridgeBio
Infigratinib is an oral FGFR3 inhibitor designed to block the overactivity of the FGFR3 receptor, which is responsible for inhibited bone growth in achondroplasia. By halting signaling at its source, infigratinib aims to promote linear growth and improve body proportionality. Positive topline results from the Phase 3 PROPEL 3 trial demonstrated a significant increase in annualized height velocity (+1.74 cm/year over placebo) and the first statistically significant improvement in upper-to-lower body proportionality in children aged 3 to 8 years. It has received Breakthrough Therapy and Orphan Drug designations from the FDA. Currently, infigratinib is in Phase III clinical development.

• Navepegritide (TransCon CNP): Ascendis Pharma
Navepegritide is a long-acting prodrug of C-type natriuretic peptide (CNP) designed to provide continuous exposure to active CNP to stimulate bone growth. It is administered via a subcutaneous injection once weekly, offering a potential advantage over daily therapies. Clinical data showed a statistically significant improvement in annualized growth velocity (5.89 cm/year vs. 4.41 cm/year for placebo) in children aged 2 to 11 years. Beyond height, navepegritide has shown potential improvements in lower limb alignment and health-related quality of life. It is currently under FDA Priority Review with a decision expected in late 2025.

• TYRA-300: Tyra Biosciences, Inc.
TYRA-300 is a selective FGFR3 inhibitor designed to specifically block FGFR3 activity while minimizing off-target effects on other receptors like FGFR1. This precision approach is intended to manage skeletal dysplasias and their associated complications with a favorable safety profile. The drug is being developed to address the root genetic cause of achondroplasia and improve the long-term quality of life for affected individuals. Currently, TYRA-300 is undergoing evaluation in Phase I clinical trials.

For more information on the Achondroplasia Emerging Drugs Profile, download DelveInsight's comprehensive Achondroplasia Pipeline Insight report @ https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Achondroplasia Pipeline Report Provides

• Detailed insights about companies developing therapies for achondroplasia, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for achondroplasia treatment.
• Achondroplasia companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Achondroplasia drugs under development based on stage of development, route of administration, target receptor, and molecular type.
• Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the achondroplasia market.

Learn more about achondroplasia drug opportunities in our comprehensive achondroplasia pipeline report @ https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Achondroplasia Companies and Competitive Landscape

There are 15+ key companies, including QED Therapeutics, Inc., Ascendis Pharma, Tyra Biosciences, BridgeBio, BioMarin Pharmaceutical, Sanofi, Pfizer, and ProLynx, developing therapies for achondroplasia, with candidates spanning from discovery to Phase III development.

DelveInsight's achondroplasia pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Achondroplasia products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in achondroplasia treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/achondroplasia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Achondroplasia Pipeline Report

• Coverage: Global
• Achondroplasia Companies: QED Therapeutics, Inc., Ascendis Pharma, Tyra Biosciences, BridgeBio, BioMarin Pharmaceutical, Sanofi, Pfizer, and others.
• Achondroplasia Therapies: Infigratinib, Navepegritide (TransCon CNP), TYRA-300, and other pipeline candidates.
• Achondroplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Achondroplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.